Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qin-Jing Pan

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Journal of the National Cancer Institute|January 25, 2012
Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening methodFang-Hui Zhao, Adam K Lewkowitz, Feng Chen, et al.
International Journal of Cancer|April 11, 2012
Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studiesFang-Hui Zhao, Adam K Lewkowitz, Shang-Ying Hu, et al.
International Journal of Cancer|April 18, 2014
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trialFeng-Cai Zhu, Wen Chen, Yue-Mei Hu, et al.
Nature Communications|April 13, 2025
Deep learning enabled liquid-based cytology model for cervical precancer and cancer detectionPeng Xue, Le Dang, Ling-Hua Kong, et al.
Cancer Medicine|December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Cancer Medicine|July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute|May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialYou-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Journal of the National Cancer Institute|January 25, 2012
Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening methodFang-Hui Zhao, Adam K Lewkowitz, Feng Chen, et al.
International Journal of Cancer|April 11, 2012
Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studiesFang-Hui Zhao, Adam K Lewkowitz, Shang-Ying Hu, et al.
International Journal of Cancer|April 18, 2014
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trialFeng-Cai Zhu, Wen Chen, Yue-Mei Hu, et al.
Nature Communications|April 13, 2025
Deep learning enabled liquid-based cytology model for cervical precancer and cancer detectionPeng Xue, Le Dang, Ling-Hua Kong, et al.
Cancer Medicine|December 21, 2016
Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25 years: event-triggered analysis of a randomized controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
Cancer Medicine|July 16, 2019
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trialFeng-Cai Zhu, Shang-Ying Hu, Ying Hong, et al.
The Lancet. Infectious Diseases|June 30, 2026
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trialHong-Xing Pan, Zhao-Feng Bi, Yu-Lin Jing, et al.
The Lancet. Infectious Diseases|August 29, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trialFang-Hui Zhao, Ting Wu, Yue-Mei Hu, et al.
Journal of the National Cancer Institute|May 16, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical TrialYou-Lin Qiao, Ting Wu, Rong-Cheng Li, et al.
Pageof 7